Elite Pharmaceuticals Inc /NV/
Elite Pharmaceuticals, Inc. develops, manufactures, and commercializes generic and specialty pharmaceutical products, with a focus on controlled-release and abuse-deterrent formulations. The company also relies on licensing, marketing, and distribution arrangements, which means a meaningful part of its business depends on partners, a small number of products, and a concentrated customer base.
Tilikausi 2026 · muutos edellisvuodesta
Kehitys 2021–2026
Liiketoiminta
Osuus liikevaihdostaApproved generic drug products sold through wholesalers, pharmacies, and other trade channels.
Extended-release dosage forms designed to deliver active ingredients over time.
Products such as SequestOx™ intended to reduce abuse potential in opioid formulations.
Revenue earned through manufacturing fees, profit splits, and commercialization agreements.
Tuotteet
Raportoitu · osuus liikevaihdosta- Indirect Sales to Wholesalers55,4 %
- Direct Sales to Wholesalers43,8 %
- Unscheduled Products Licensing Fees0,4 %
- Scheduled Products Licensing Fees0,3 %
Lähde: 10-K FY2026, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Elite sells primarily into a concentrated pharmaceutical channel rather than directly to end consumers. Its customers include wholesalers, retail drug chains, managed care organizations, group purchasing organizations, and marketing/license partners that buy products or commercial rights because they need low-cost generic supply and specialized formulations. The company also depends on a small number of large customers, making order timing and purchasing patterns especially important.
Buy generic products in bulk for redistribution to pharmacies and other end customers; they matter because they control access to large downstream demand.
Purchase products through negotiated contracts and influence pricing through consolidation and buying leverage.
Shape demand by steering utilization toward lower-cost generics and by pressuring pricing and rebates.
Buy through contract channels and drive chargebacks, rebates, and price concessions.
Commercialize or distribute selected products and share economics with Elite under licensing arrangements.
Strategia
Elite's strategy centers on developing and commercializing a small portfolio of differentiated generic and specialty products while expanding through collaborators and licensees. The company is also trying to manage pricing pressure by working with managed care and insurer channels, but its filings show that execution risk remains high because product launches, regulatory approvals, and partner commitment all matter to revenue realization.
Future revenue depends on successful development, approval, and commercialization of product candidates.
Collaborators and licensees can extend market reach without requiring Elite to build a large direct sales force.
Retail chains, wholesalers, and managed care organizations have significant bargaining power and can pressure margins.
Maantiede
Elite is a U.S.-based pharmaceutical company, and the available filings emphasize domestic regulatory, reimbursement, and distribution exposure. The business is tied to U.S. wholesalers, pharmacies, managed care organizations, and FDA/DEA oversight, so the U.S. market is the key operating geography. No country-level revenue split was disclosed in the provided excerpts.
Riskit
Elite faces concentrated-product and concentrated-customer risk, which makes revenue vulnerable to the loss of a single product, customer, or partner. Its filings also highlight regulatory, manufacturing, and litigation risks typical of pharmaceuticals, including FDA/DEA constraints, supply interruptions at a sole facility, and patent or pricing disputes that can quickly affect commercialization and cash flow.
- Regulatory approval and complianceVaikutus: KorkeaTodennäköisyys: Korkea
Pharmaceutical products require FDA and DEA approvals and ongoing compliance, which can delay launches or restrict supply.
Kohdistuu: SequestOx™ NDA received a CRL; DEA quotas may limit ingredients
- Customer concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen
A small number of customers account for most revenue, so lost orders would quickly hit sales and cash flow.
Kohdistuu: Six largest customers accounted for over 80% of revenues
- Product concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen
Revenue depends on a limited number of products, increasing sensitivity to competition, regulation, or supply issues.
Kohdistuu: Top four product families exceeded 90% of allocated revenues
- Manufacturing interruptionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Operations at a sole facility create a single point of failure for production and fulfillment.
Kohdistuu: Sole facility operations
- Pricing and reimbursement pressureVaikutus: KeskitasoTodennäköisyys: Korkea
Consolidated wholesalers, chains, and managed care buyers can demand discounts and rebates.
Kohdistuu - Litigation and IP disputesVaikutus: KeskitasoTodennäköisyys: Korkea
Generic and controlled-substance products face patent, fraud-and-abuse, and product liability claims.
Kohdistuu: At-risk launches and infringement allegations
Kirjanpito
Harkinnanvaraiset erätRevenue is reduced by chargebacks, rebates, discounts, returns, and other deductions, so reserve accuracy drives reported sales.
Vaikutus: Can materially change quarterly and annual revenue
Wholesaler and government pricing programs create timing and estimation risk between gross and net revenue.
Vaikutus: Affects net sales and gross margin
Realizability depends on future taxable income assumptions, which are uncertain for a concentrated product company.
Vaikutus: Can affect tax expense and equity
IP disputes, recalls, and government investigations may require accruals or disclosures depending on probability and magnitude.
Vaikutus: Can affect expenses and liabilities
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Elite Health Systems Inc.
EHSI · Services-Specialty Outpatient Facilities, NEC
CTT Pharmaceutical Holdings, Inc.
CTTH · Pharmaceutical Preparations
Olema Pharmaceuticals, Inc.
OLMA · Pharmaceutical Preparations
Olema Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for…
MIRA Pharmaceuticals, Inc
MIRA · Pharmaceutical Preparations
Teva Pharmaceutical Industries Limited
TEVA · Pharmaceutical Preparations
LFTD Partners Inc.
LIFD · Pharmaceutical Preparations
Päivitetty: 24.9.2026